Endometrial Stromal Sarcoma: Etiology, Prognosis and Treatment Options Journal Article
| Authors: | Maluf, F. C.; Aghajanian, C.; Spriggs, D. |
| Article Title: | Endometrial Stromal Sarcoma: Etiology, Prognosis and Treatment Options |
| Abstract: | Uterine sarcomas comprise 2-3% of all uterine malignancies. Tumors in this category are, in order of decreasing incidence, carcinosarcoma, leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. Endometrial stromal sarcomas are divided into low- and high-grade according to tumor cell morphology and mitotic rate. Low-grade tumors are characterized by a slow growth pattern, presence of estrogen and/or progesterone receptors, and an indolent clinical course with late recurrences. Despite this indolent course, 37-60% of patients with early-stage disease experience recurrent disease. High-grade stromal sarcomas, on the other hand, exhibit more aggressive biological behavior and poor outcome. The standard treatment for localized endometrial stromal sarcomas is total abdominal hysterectomy and bilateral salpingo-oophorectomy. Adjuvant radiation therapy appears to reduce locoregional failure, although its benefit in terms of overall survival is unknown. Progestogens have been considered first-line therapy in recurrent low-grade tumors, with durable response rates of approximately 50%. Some authors also favor their use in the adjuvant setting, although no clear data exist to support this indication as a standard approach. Other hormonal approaches such as aromatase inhibitors may provide an alternative to progestogens in light of a more favorable toxicity profile and similar antitumor activity. Chemotherapy, including anthracyclines, is generally reserved for recurrent low-grade tumors that progress on hormonal therapies and for high-grade lesions that usually lack hormone receptors. The combination of chemotherapy and hormones may be considered in highly symptomatic patients or in those with high-volume, life-threatening disease. In summary, endometrial stromal sarcoma of the uterus is a rare disease that should be treated with radical surgery. Prognostic factors according to tumor stage, mitotic count, and tumor grade can, to some extent, predict biologic tumor behavior and prognosis. The role of postoperative radiation therapy and adjuvant progestogens, particularly for low-grade disease, remains to be defined. Recurrent or metastatic disease should be treated with systemic therapy, and the choice between hormonal therapy and chemotherapy should be based on histologic characteristics including mitotic count, cell morphology, and estrogen and progesterone receptor status. Salvage surgery and/or radiation have been associated with some long-term remissions, and can be considered as part of the multimodality approach in selected cases. New prognostic markers and specific therapeutic targets are clearly needed in this rare disease. |
| Keywords: | immunohistochemistry; cancer surgery; clinical trial; drug tolerability; review; cancer recurrence; cisplatin; doxorubicin; fluorouracil; ascites; cancer combination chemotherapy; cancer risk; drug efficacy; drug potentiation; side effect; paclitaxel; cancer radiotherapy; methotrexate; cancer staging; nuclear magnetic resonance imaging; positron emission tomography; cancer grading; salpingooophorectomy; cancer palliative therapy; lymphadenectomy; carboplatin; dacarbazine; protein bcl 2; computer assisted tomography; etoposide; bleeding; thoracotomy; pelvis lymphadenectomy; tumor differentiation; aromatase inhibitor; cyclophosphamide; vincristine; protein p53; cancer mortality; gonadorelin; ifosfamide; cancer invasion; molecular marker; lung metastasis; thromboembolism; fluorodeoxyglucose f 18; dactinomycin; tamoxifen; epirubicin; mitomycin c; thorax radiography; ovary metastasis; letrozole; castration; cancer classification; mesna; peritoneum metastasis; gastrointestinal disease; abdominal hysterectomy; lymphadenopathy; uterus sarcoma; chlorambucil; antiestrogen; hematologic disease; endometrium biopsy; protein mdm2; megestrol acetate; hormone substitution; common acute lymphoblastic leukemia antigen; gestagen; weight gain; vagina bleeding; mitosis index; endometrium sarcoma; ploidy; prognosis; human; priority journal |
| Journal Title: | American Journal of Cancer |
| Volume: | 3 |
| Issue: | 1 |
| ISSN: | 1175-6357 |
| Publisher: | Springer |
| Date Published: | 2004-01-01 |
| Start Page: | 13 |
| End Page: | 23 |
| Language: | English |
| DOI: | 10.2165/00024669-200403010-00002 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Am. J. Cancer -- Cited By (since 1996):2 -- Export Date: 16 June 2014 -- CODEN: AJCMC -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
607Aghajanian -
325Spriggs
Related MSK Work